Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Works matching IS 11707690 AND DT 2021 AND VI 39 AND IP 4
Results: 10
1
2
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction Success.
- Published in:
- 2021
- By:
- Publication type:
- journal article
3
The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases.
- Published in:
- 2021
- By:
- Publication type:
- Letter
4
Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
- Published in:
- 2021
- By:
- Publication type:
- Letter
5
Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome".
- Published in:
- 2021
- By:
- Publication type:
- Letter
6
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 4, p. 383, doi. 10.1007/s40273-021-01003-y
- By:
- Publication type:
- Article
7
Macrovascular Risk Equations Based on the CANVAS Program.
- Published in:
- 2021
- By:
- Publication type:
- journal article
8
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 4, p. 399, doi. 10.1007/s40273-020-00998-0
- By:
- Publication type:
- Article
9
EQ-5D-Y Value Set for Slovenia.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 4, p. 463, doi. 10.1007/s40273-020-00994-4
- By:
- Publication type:
- Article
10
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 4, p. 421, doi. 10.1007/s40273-020-00992-6
- By:
- Publication type:
- Article